8 februari 2017: Bron: ASH 2016 San Diego.

Wanneer zwaar voorbehandelde patienten met vergevorderde botkanker - multiple myeloma (Kahler) een combinatie behandeling krijgen van Nelfinavir plus bortezomib en dexamethasone dan bereikte 65% van de deelnemende patienten (22 uit 34 patienten) alnsog een gedeelteljike remissie van 50 procent of meer. De algemene kliniche respons, waarin ook stabiele ziekte en minimale remissies werden meegenomen was maar liefst 86 procent.

nelvir_nelfinavir_tablets_250mg

Tijdens de ASH werden dit de kernpunten genoemd van deze studie:

Nelfinavir in Multiple Myeloma

  • Het antiretrovirale medicijn nelfinavir toont sterke klinische activiteit bij zwaarvoorbehandelde patienten met resistente teruggekeerde multiple myeloma (Kahler)  volgens een kleine fase II studie met 34 patienten.
  • De response was 65%, inclusief een 15% zeer goede gedeelteljike remissie, van 50% of meer. Bij patiënten met een hoog risico met zogenaamde  "cytogenetics", was de response 77%.
  • De verdere ontwikkeling van dit medicijn met veel potentie is echter onzeker omdat het patent op nelfinavir afloopt.

Nelfinavir studie bij MM - Kahler

Bron: https://ash.confex.com/ash/2016/webprogram/Paper89818.html

Studieresultaten:

Positieve klinische reacties werd gezien bij 22 patiënten uit 34 (= 65%) die de nelfinavir plus behandeling kregen. Er werden zeer goede remissies gezien (tussen de 50 en 100 procent) bij 5 patienten (15%) en gedeeltelijke remissies (een PR van gelijk of meer dan 50%) bij 17 patiënten (50%). 3 patiënten (9%) had een remissie kleiner dan 50% en 4 anderen (12%) hadden stabiele ziekte, dus stopte de progressie van de ziekte, resulterend in een klinische respons van 86%. Klinische effectiviteit werd algemeen gezien bij alle patienten ongeacht de verschillende voorbehandelingen van bv. stamceltransplantatie of chemo of andere behandelingen.

Ik kan niet zo heel veel meer vertellen over deze studie: The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)

behalve dan het abstract zoals dat op de ASH werd gepresenteerd. Maar bedenk dat alle patienten minimaal 5 andere behandeliingen eerder hebben gehad en dan toch nog zo goed reageerden op deze behandeling is natuurlijk heel goed nieuws.

Nelfinavir in combination with bortezomib and dexamethasone (NVd) is a reasonable, active, safe and widely available treatment option for patients with proteasome inhibitor-refractory multiple myeloma. The objective response rate of 65% observed in this very advanced, heavily pretreated, mostly dual-refractory patient population is exceptional. Our results warrant further development of nelfinavir as a sensitizing drug for proteasome inhibitor-based treatments and promising new agent for MM therapy.

The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)

Myeloma: Therapy, excluding Transplantation
Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma: Therapy, excluding Transplantation: New Agents for Multiple Myeloma
Sunday, December 4, 2016: 4:30 PM
Hall AB (San Diego Convention Center)

Christoph Driessen, MD, PhD1, Rouven Müller, MD2*, Urban Novak, MD3*, Nathan Cantoni, MD4, Daniel Betticher5*, Nicolas Mach6*, Michael Gregor7*, Panagiotis Samaras, MD8*, Catherine Berset9*, Stephanie Rondeau9*, Hanne Hawle, MD9*, Felicitas Hitz, MD10*, Thomas Pabst, MD, PhD11 and Thilo Zander, MD12*

1Department of Oncology and Haematology, Kantonsspital St.Gallen, St.Gallen, Switzerland
2Hematology, University Hospital and University of Zurich, Zurich, Switzerland
3Universitatsspital Bern, Bern, Switzerland
4Division of Haematology, Cantonal Hospital Aarau, Aarau, Switzerland
5Hôpital Fribourgeois, Fribourg, Switzerland
6University Hospital Geneva, Geneva,, Switzerland
7Division of Hematology, Cantonal Hospital of Lucerne, Lucerne, Switzerland
8Universitaetsspital Zurich, Zurich, Switzerland
9SAKK Coordinating Center, Bern, Switzerland
10Kantonsspital St.Gallen, St.Gallen, Switzerland
11Department of Hematology, Bern University Hospital, Bern, Switzerland
12Luzerner Kantonsspital, Luzern, Switzerland

Rationale: Proteasome inhibitor-refractory multiple myeloma (MM) patients are a difficult to treat population with a very poor prognosis. The activity of registered, current or next generation MM drugs (pomalidomide, carfilzomib, daratumumab) in heavily pretreated, proteasome inhibitor-refractory MM is in the range of 30%. The biology of proteasome inhibitor resistance is driven by adaptive downregulation of the unfolded protein response (UPR), which regulates plasma cell maturation and sensitivity to proteasome inhibitor treatment (Leung-Hagesteijn C. et al., Cancer Cell 2013 Sep 9;24(3):289-304). The oral HIV protease inhibitor nelfinavir (NFV) has anti-MM activity in vivo, triggers UPR activation, sensitizes MM to proteasome inhibitors and overcomes proteasome inhibitor resistance in vitro. Combination therapy with NFV and bortezomib (BTZ) showed UPR activation in vivo and strong signals of activity in bortezomib-refractory MM in the SAKK 65/08 phase I trial  (Driessen C. et al., Haematologica 2016 Mar;101(3):346-55).

Objective: We performed a prospective, multicenter phase II trial to assess the activity of nelfinavir, bortezomib and dexamethasone (NVd) in proteasome inhibitor-refractory MM.

Methods: Patients with progressing, measurable, proteasome inhibitor-refractory MM (IMWG criteria) were included in this multicenter phase II trial. Further selection criteria included WHO performance status ≤ 3, platelets ≥ 50 x 109/L, hemoglobin ≥ 80 g/L (both may be achieved by transfusion) and adequate hepatic function. Concomitant use of other anti-cancer medication or radiotherapy, except for local pain control, was excluded. Patient age or prior number or types of therapy were not limited. Simon’s two stage design was used to differentiate a promising activity (best response at any time point, partial response (PR) or better, ≥ 35 %) from an uninteresting activity (≤ 15% PR; power 80%, alpha 5%).

Results: 34 patients were treated with oral nelfinavir 2500 mg days 1-14 b.i.d. in combination with bortezomib + dexamethasone (BTZ 1.3 mg/m2 days 1, 4, 8, 11, dexamethasone 20 mg p.o. days 1-2, 4-5, 8-9, 11-12) for a maximum of 6 21-day cycles at 9 SAKK trial sites throughout Switzerland. Patients (median age 67.5 years, range 42-82 years) had a median of 5 (range 2-12) prior therapy lines, 26 (76%) patients had prior high dose chemotherapy, and 13 (39%) had known poor prognosis cytogenetic abnormalities. All treated patients had proteasome inhibitor refractory MM according to IMWG criteria, i.e. they had progressed during or within 60 days after adequately dosed proteasome inhibitor-containing therapy. Moreover, 26 (76%) patients were lenalidomide-refractory by IMWG criteria (double refractory). Trial therapy is still ongoing in 2 patients.  The median number of treatment cycles delivered per patient is 4. 22 patients achieved an objective response with a PR or better, resulting in an overall response rate (OR) of 65% (90% CI 49.2%-75.7%) to date. VGPR was reached in 5 patients, PR in 17 patients, MR in 3 patients, SD in 4 patients and PD in 3. In patients double-refractory for proteasome inhibitors and lenalidomide, the OR was 69%, in patients with poor prognosis cytogenetic abnormalities it was 77%. The OR was independent from the number of prior therapy lines (OR rate 69% with < 5 prior therapy lines, OR rate 61% with ≥ 5 prior lines). Most frequent > grade (G) 2 adverse events to date were anemia (G3 29%), thrombocytopenia (G3 24%, G4 18%), infections (G3 24%, G4 9%, G5 3%), hyperglycemia (G3 18%, G4 3%) and fatigue (G3 12%). Six patients maintained their PR or better for the full 6 cycles per protocol while on study. Four patients continued NVd therapy on a compassionate use basis after completing the study. Updated final data will be provided at the meeting.

Conclusion: Nelfinavir in combination with bortezomib and dexamethasone (NVd) is a reasonable, active, safe and widely available treatment option for patients with proteasome inhibitor-refractory multiple myeloma. The objective response rate of 65% observed in this very advanced, heavily pretreated, mostly dual-refractory patient population is exceptional. Our results warrant further development of nelfinavir as a sensitizing drug for proteasome inhibitor-based treatments and promising new agent for MM therapy.

Figure 1. Maximum relative change in serum M-protein or serum free light chain concentration in individual evaluable patients.

Disclosures: Driessen: Mundipharma-EDO: Honoraria, Membership on an entity's Board of Directors or advisory committees; celgene: Consultancy; janssen: Consultancy. Samaras: Celgene (Adboard, educational talk), Amgen (adboard), Takeda (Adboard), Roche (Adboard), Sanofi (Adboard), Novartis (Adboard): Consultancy, Honoraria. Zander: Bristol Myers, Celgene, Amgen, Mundipharma, Janssen-Cilag, Takeda Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees.


Plaats een reactie ...

Reageer op "Nelfinavir, een HIV remmer, plus bortezomib (velcade) geeft uitstekende resultaten - 65 procent bereikte PR - bij zwaar voorbehandelde patienten met vergevorderde multiple myeloma, Kahler"


Gerelateerde artikelen
 

Gerelateerde artikelen

Nederlandse studie geeft overzicht >> Belangrijke abstracten van >> CAR T-celtherapie met het >> Meta-analysis Shows Association >> Hoewel overall overleving >> Cryotherapie tijdens toediening >> Daratumumab (Darzalex) in >> Elotuzumab - een immuuntherapeutisch >> Genentest blijkt voorspellende >> lenalidomide na autologe stamceltransplantatie >>